Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor

Prasugrel and ticagrelor are potent oral platelet P2Y(12) inhibitors and are recommended over clopidogrel in patients with acute coronary syndrome (ACS). Oral platelet P2Y(12) inhibitors are characterized by varying degrees of pharmacodynamic response profiles as assessed by a variety of commerciall...

Descripción completa

Detalles Bibliográficos
Autores principales: Angiolillo, Dominick J., Been, Latonya, Rubinstein, Marc, Martin, Michael, Rollini, Fabiana, Franchi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049919/
https://www.ncbi.nlm.nih.gov/pubmed/33582955
http://dx.doi.org/10.1007/s11239-021-02386-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049919/
https://www.ncbi.nlm.nih.gov/pubmed/33582955
http://dx.doi.org/10.1007/s11239-021-02386-7

Ejemplares similares